A high proportion of naive-like and stem cell memory-like T cells in the manufactured CAR T cell product is associated with better and longer-lasting clinical benefit in patients with non-Hodgkin lymphoma, according to a large multicenter analysis of clinical trial samples published in Nature Medicine.
The study examined samples from patients treated with anti-CD19 CAR T cell therapy and focused on a specific subset of T cells carrying the markers CCR7 and CD45RA. Patients whose pre-infusion products contained a larger share of these naive-like and stem cell memory-like cells experienced improved and prolonged responses to the therapy.
The finding was validated in an independent external cohort that included different CAR T cell products, strengthening the case that the cellular composition of the infused product is a meaningful determinant of how well patients respond, rather than an artifact of a single trial or manufacturing approach.
CAR T cell therapy has become an important treatment option for several blood cancers, including certain lymphomas, but response rates vary widely among patients. Understanding why some patients benefit durably while others relapse or respond only briefly has been a central question for researchers and clinicians. The new analysis points to the characteristics of the infused cell product itself as one key factor.
The researchers analyzed clinical trial samples from multiple studies, pooling data across a multicenter, multi-trial cohort. By comparing the cellular makeup of pre-infusion products with patient outcomes, they identified the proportion of CCR7+CD45RA+ T cells as a correlate of improved and prolonged clinical benefit.
Naive-like and stem cell memory-like T cells are thought to retain greater capacity for self-renewal and persistence, properties that may help engineered cells survive and remain active in the body over time. The association observed in the study is consistent with that biological rationale, though the analysis is correlative and does not by itself establish that the cell subset directly causes the improved outcomes.
The validation in an independent cohort that included different products is notable because it suggests the relationship holds across manufacturing platforms and trial settings. That broadens the potential relevance of the finding for efforts to optimize CAR T cell manufacturing and for patient selection or product characterization.
The work adds to a growing body of evidence that the composition of the starting T cell population and the resulting engineered product can influence clinical results. If confirmed in further studies, the proportion of naive-like and stem cell memory-like cells could serve as a useful marker when evaluating or comparing CAR T cell products.
The analysis was published online in Nature Medicine. The authors describe the work as a comprehensive analysis of clinical trial samples from patients with non-Hodgkin lymphoma treated with anti-CD19 CAR T therapy, with the external validation cohort including different products.
12
